dimethyl sulfoxide has been researched along with Thrombopenia in 11 studies
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.
dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients were monitored for adverse events (AEs), coagulation markers, PLT responses, and hemostatic efficacy." | 2.87 | Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. ( Cancelas, JA; Dumont, LJ; Dunbar, NM; Gernsheimer, TB; Hmel, P; Housler, G; Jones, M; Kinne, B; Macdonald, VW; Medlin, S; Prakash, G; Ransom, JH; Rugg, N; Slichter, SJ; Szczepiorkowski, ZM; Valiyaveettil, M, 2018) |
| "PCs were collected from 14 women with breast cancer by a single plateletapheresis and cryopreserved in ThromboSol/2% DMSO by either direct insertion in a -80 degrees C freezer or in liquid nitrogen after computer-controlled rate (CR) freezing." | 1.31 | Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. ( Balduini, CL; Belletti, S; Da Prada, GA; Noris, P; Pedrazzoli, P; Perotti, C; Ponchio, L; Robustelli Della Cuna, G; Salvaneschi, L; Schiavo, R; Siena, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slichter, SJ | 1 |
| Dumont, LJ | 1 |
| Cancelas, JA | 1 |
| Jones, M | 1 |
| Gernsheimer, TB | 1 |
| Szczepiorkowski, ZM | 1 |
| Dunbar, NM | 1 |
| Prakash, G | 1 |
| Medlin, S | 1 |
| Rugg, N | 1 |
| Kinne, B | 1 |
| Macdonald, VW | 1 |
| Housler, G | 1 |
| Valiyaveettil, M | 1 |
| Hmel, P | 1 |
| Ransom, JH | 1 |
| Potron, G | 1 |
| Herve, P | 1 |
| Corso, S | 1 |
| Vukelja, SJ | 1 |
| Wiener, D | 1 |
| Baker, WJ | 1 |
| Vadhan-Raj, S | 1 |
| Currie, LM | 1 |
| Bueso-Ramos, C | 1 |
| Livesey, SA | 1 |
| Connor, J | 1 |
| Pedrazzoli, P | 1 |
| Noris, P | 1 |
| Perotti, C | 1 |
| Schiavo, R | 1 |
| Ponchio, L | 1 |
| Belletti, S | 1 |
| Da Prada, GA | 1 |
| Balduini, CL | 1 |
| Salvaneschi, L | 1 |
| Robustelli Della Cuna, G | 1 |
| Siena, S | 1 |
| Schiffer, CA | 1 |
| Aisner, J | 1 |
| Wiernik, PH | 1 |
| Valeri, CR | 2 |
| Feingold, H | 2 |
| Melaragno, AJ | 2 |
| Vecchione, JJ | 1 |
| Carciero, R | 1 |
| Talarico, L | 1 |
| Weintraub, L | 1 |
| Schwarzenberg, L | 1 |
| Gardner, FH | 1 |
| Cohen, P | 1 |
| Johnson, SA | 1 |
| Rebuck, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding[NCT02078284] | Phase 1 | 28 participants (Actual) | Interventional | 2014-11-05 | Completed | ||
| Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With Platelet Refractoriness[NCT05761457] | 25 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects with any signs or symptoms of thrombotic events. (NCT02078284)
Timeframe: 6 days after transfusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 With 0.5 Units of CPP | 0 |
| Cohort 2 With 1 Unit of CPP | 0 |
| Cohort 3 With 2 Units of CPP | 0 |
| Cohort 4 With 3 Units of CPP | 0 |
| 1 Unit of LSP | 0 |
Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital sign AEs summarized by severity. (NCT02078284)
Timeframe: day of thru 6 days after transfusion
| Intervention | adverse events (Number) | ||||
|---|---|---|---|---|---|
| Total number of AEs | Total mild AEs | Total moderate AEs | Total Severe AEs | Total Life-threatening or Fatal AEs | |
| 1 Unit of LSP | 5 | 5 | 0 | 0 | 0 |
| Cohort 1 With 0.5 Units of CPP | 8 | 6 | 1 | 0 | 1 |
| Cohort 2 With 1 Unit of CPP | 18 | 11 | 3 | 1 | 3 |
| Cohort 3 With 2 Units of CPP | 6 | 1 | 5 | 0 | 0 |
| Cohort 4 With 3 Units of CPP | 21 | 9 | 5 | 1 | 6 |
Corrected Count Increments Expressed in units of mm^2/(µL*10¹¹ platelets) (CCI) in the 6 hour period after the study platelet transfusion and on Day 2 (approximately 24 hours after the study platelet transfusion) (NCT02078284)
Timeframe: Day 1 up to 6 hrs after transfusion and Day 2 approx 24 hrs after transfusion
| Intervention | mm^2/(μL*1011 platelets) (Mean) | |
|---|---|---|
| CII: Day 1 up to 6 hrs after | CII: Day 2 | |
| 1 Unit of LSP | 14.8 | 4.13 |
| Cohort 1 With 0.5 Units of CPP | 2.40 | 5.19 |
| Cohort 2 With 1 Unit of CPP | 3.10 | -2.05 |
| Cohort 3 With 2 Units of CPP | 2.73 | 5.63 |
| Cohort 4 With 3 Units of CPP | 3.70 | 2.35 |
Count Increment expressed in units of platelets (x10^3 µL) (CI) (NCT02078284)
Timeframe: On Day 1 up to 6 hours after transfusion and on Day 2 approximately 24 hours after transfusion
| Intervention | platelets*10^3 µL (Mean) | |
|---|---|---|
| Day 1 Up to 6 Hours After | Day 2 | |
| 1 Unit of LSP | 30.5 | 8.75 |
| Cohort 1 With 0.5 Units of CPP | 1.20 | 2.80 |
| Cohort 2 With 1 Unit of CPP | 3.67 | -2.57 |
| Cohort 3 With 2 Units of CPP | 6.50 | 12.5 |
| Cohort 4 With 3 Units of CPP | 13.2 | 10.7 |
Number of subjects who experienced AEs at specific levels of severity. Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital signs were evaluated. (NCT02078284)
Timeframe: day of thru 6 days after transfusion
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Total Patients with Any AE | Total Patients with Mild AEs | Total Patients with Moderate AEs | Total Patients with Severe AEss | Total Patients with Life-threatening or Fatal AEs | Related to Investigational Product | ||
| 1 Unit of LSP | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cohort 1 With 0.5 Units of CPP | 4 | 4 | 4 | 1 | 0 | 1 | 1 |
| Cohort 2 With 1 Unit of CPP | 6 | 6 | 4 | 1 | 1 | 1 | 2 |
| Cohort 3 With 2 Units of CPP | 3 | 3 | 1 | 3 | 0 | 2 | 2 |
| Cohort 4 With 3 Units of CPP | 5 | 5 | 5 | 1 | 1 | 2 | 2 |
1 review available for dimethyl sulfoxide and Thrombopenia
| Article | Year |
|---|---|
Platelet transfusions.
Topics: Animals; Antibodies; Blood Platelets; Blood Preservation; Blood Transfusion; Blood Volume Determinat | 1970 |
1 trial available for dimethyl sulfoxide and Thrombopenia
| Article | Year |
|---|---|
Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia.
Topics: Adult; Aged; Blood Preservation; Cell-Derived Microparticles; Cryopreservation; Cryoprotective Agent | 2018 |
9 other studies available for dimethyl sulfoxide and Thrombopenia
| Article | Year |
|---|---|
[Preservation of platelets by freezing].
Topics: Blood Platelets; Blood Preservation; Blood Transfusion; Cryoprotective Agents; Dimethyl Sulfoxide; F | 1982 |
Diffuse alveolar hemorrhage following autologous bone marrow infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1993 |
Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO.
Topics: Blood Platelets; Cryopreservation; Cryoprotective Agents; Dimethyl Sulfoxide; Female; Humans; Micros | 1999 |
Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study.
Topics: Blood Transfusion, Autologous; Breast Neoplasms; Cryopreservation; Cryoprotective Agents; Dimethyl S | 2000 |
Frozen autologous platelet transfusion for patients with leukemia.
Topics: Adult; Blood Cell Count; Blood Platelets; Blood Preservation; Blood Transfusion, Autologous; Dimethy | 1978 |
Cryopreservation of dog platelets with dimethyl sulfoxide: therapeutic effectiveness of cryopreserved platelets in the treatment of thrombocytopenic dogs, and the effect of platelet storage at -80 degrees C.
Topics: Animals; Blood Platelets; Blood Preservation; Blood Transfusion; Dimethyl Sulfoxide; Dogs; Freezing; | 1986 |
Cryopreservation of human platelets using 6% dimethyl sulfoxide and storage at -80 degrees C. Effects of 2 years of frozen storage at -80 degrees C and transportation in dry ice.
Topics: Blood Platelets; Blood Preservation; Blood Transfusion; Blood Transfusion, Autologous; Cell Survival | 1985 |
[The effectiveness of platelet transfusions].
Topics: Blood Platelets; Blood Preservation; Blood Transfusion; Dimethyl Sulfoxide; Hemorrhage; Humans; Leuk | 1967 |
Platelet preservation and transfusion.
Topics: Blood Platelets; Blood Preservation; Blood Transfusion; Citrates; Dimethyl Sulfoxide; Edetic Acid; G | 1968 |